APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Drug

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

Selected research

Industry Growth & Trends

Global Biosimilar Drug Industry Growth and Trends Forecast to 2032

20 December 202598 pages

Choose your research edition.

Industry ResearchBiosimilar Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Drug Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Biosimilar Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.

Read the full market overview

East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.

In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.

Report Scope

This report provides a structured, data-driven view of the global Biosimilar Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biosimilar Drug market size, estimates, and forecasts are presented in terms of sales volume (K Dose) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biosimilar Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biosimilar Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Biosimilar Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biosimilar Drug Market by Company

CP Guojian Pharma

Biotech Pharma

Celgen Pharma

Henlius

Amgen

Eli Lilly

Sandoz

Changchun High Tech

Innovent

Biosimilar Drug Segment by Type

Injection

Tablets

Other Types

Biosimilar Drug Segment by Application

Ankylosing Spondylitis

Tumor

Rheumatoid Arthrtis

Cardiovascular

Other Application

Biosimilar Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilar Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Biosimilar Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injection Table 2. Major Company of Tablets Table 3. Major Company of Other Types Table 4. Global Biosimilar Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Biosimilar Drug Sales by Type (2021-2026) & (K Dose) Table 6. Global Biosimilar Drug Sales Market Share in Volume by Type (2021-2026) Table 7. Global Biosimilar Drug Sales by Type (2021-2026) & (US$ Million) Table 8. Global Biosimilar Drug Sales Market Share in Value by Type (2021-2026) Table 9. Global Biosimilar Drug Price by Type (2021-2026) & (USD/Dose) Table 10. Global Biosimilar Drug Sales by Type (2027-2032) & (K Dose) Table 11. Global Biosimilar Drug Sales Market Share in Volume by Type (2027-2032) Table 12. Global Biosimilar Drug Sales by Type (2027-2032) & (US$ Million) Table 13. Global Biosimilar Drug Sales Market Share in Value by Type (2027-2032) Table 14. Global Biosimilar Drug Price by Type (2027-2032) & (USD/Dose) Table 15. North America Biosimilar Drug Sales by Type (2021-2026) & (K Dose) Table 16. North America Biosimilar Drug Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Biosimilar Drug Sales by Type (2021-2026) & (K Dose) Table 18. Europe Biosimilar Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Biosimilar Drug Sales by Type (2021-2026) & (K Dose) Table 20. Asia-Pacific Biosimilar Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Biosimilar Drug Sales by Type (2021-2026) & (K Dose) Table 22. Latin America Biosimilar Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Biosimilar Drug Sales by Type (2021-2026) & (K Dose) Table 24. Middle East and Africa Biosimilar Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Biosimilar Drug Industry Trends Table 26. Biosimilar Drug Industry Drivers Table 27. Biosimilar Drug Industry Opportunities and Challenges Table 28. Biosimilar Drug Industry Restraints Table 29. Global Biosimilar Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Biosimilar Drug Revenue Market Share by Company (2021-2026) Table 31. Global Biosimilar Drug Sales by Company (2021-2026) & (K Dose) Table 32. Global Biosimilar Drug Sales Share by Company (2021-2026) Table 33. Global Biosimilar Drug Market Price by Company (2021-2026) & (USD/Dose) Table 34. Global Biosimilar Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Biosimilar Drug Major Company Production Sites and Headquarters Table 36. Global Biosimilar Drug Company, Product Type & Application Table 37. Global Biosimilar Drug Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Biosimilar Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Biosimilar Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Biosimilar Drug Sales by Region (2021-2026) & (K Dose) Table 42. Global Biosimilar Drug Sales Market Share in Volume by Region (2021-2026) Table 43. Global Biosimilar Drug Sales by Region (2021-2026) & (US$ Million) Table 44. Global Biosimilar Drug Sales Market Share in Value by Region (2021-2026) Table 45. Global Biosimilar Drug Sales (K Dose), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 46. Global Biosimilar Drug Sales by Region (2027-2032) & (K Dose) Table 47. Global Biosimilar Drug Sales Market Share in Volume by Region (2027-2032) Table 48. Global Biosimilar Drug Sales by Region (2027-2032) & (US$ Million) Table 49. Global Biosimilar Drug Sales Market Share in Value by Region (2027-2032) Table 50. Global Biosimilar Drug Sales (K Dose), Value (US$ Million), Price (USD/Dose) and Gross Margin (2027-2032) Table 51. Global Biosimilar Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Biosimilar Drug Sales by Application (2021-2026) & (K Dose) Table 53. Global Biosimilar Drug Sales Market Share in Volume by Application (2021-2026) Table 54. Global Biosimilar Drug Sales by Application (2021-2026) & (US$ Million) Table 55. Global Biosimilar Drug Sales Market Share in Value by Application (2021-2026) Table 56. Global Biosimilar Drug Price by Application (2021-2026) & (USD/Dose) Table 57. Global Biosimilar Drug Sales by Application (2027-2032) & (K Dose) Table 58. Global Biosimilar Drug Sales Market Share in Volume by Application (2027-2032) Table 59. Global Biosimilar Drug Sales by Application (2027-2032) & (US$ Million) Table 60. Global Biosimilar Drug Sales Market Share in Value by Application (2027-2032) Table 61. Global Biosimilar Drug Price by Application (2027-2032) & (USD/Dose) Table 62. North America Biosimilar Drug Sales by Application (2021-2026) & (K Dose) Table 63. North America Biosimilar Drug Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Biosimilar Drug Sales by Application (2021-2026) & (K Dose) Table 65. Europe Biosimilar Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Biosimilar Drug Sales by Application (2021-2026) & (K Dose) Table 67. Asia-Pacific Biosimilar Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Biosimilar Drug Sales by Application (2021-2026) & (K Dose) Table 69. Latin America Biosimilar Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Biosimilar Drug Sales by Application (2021-2026) & (K Dose) Table 71. Middle East and Africa Biosimilar Drug Sales by Application (2021-2026) & (US$ Million) Table 72. CP Guojian Pharma Company Information Table 73. CP Guojian Pharma Business Overview Table 74. CP Guojian Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 75. CP Guojian Pharma Biosimilar Drug Product Portfolio Table 76. CP Guojian Pharma Recent Development Table 77. Biotech Pharma Company Information Table 78. Biotech Pharma Business Overview Table 79. Biotech Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 80. Biotech Pharma Biosimilar Drug Product Portfolio Table 81. Biotech Pharma Recent Development Table 82. Celgen Pharma Company Information Table 83. Celgen Pharma Business Overview Table 84. Celgen Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 85. Celgen Pharma Biosimilar Drug Product Portfolio Table 86. Celgen Pharma Recent Development Table 87. Henlius Company Information Table 88. Henlius Business Overview Table 89. Henlius Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 90. Henlius Biosimilar Drug Product Portfolio Table 91. Henlius Recent Development Table 92. Amgen Company Information Table 93. Amgen Business Overview Table 94. Amgen Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 95. Amgen Biosimilar Drug Product Portfolio Table 96. Amgen Recent Development Table 97. Eli Lilly Company Information Table 98. Eli Lilly Business Overview Table 99. Eli Lilly Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 100. Eli Lilly Biosimilar Drug Product Portfolio Table 101. Eli Lilly Recent Development Table 102. Sandoz Company Information Table 103. Sandoz Business Overview Table 104. Sandoz Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 105. Sandoz Biosimilar Drug Product Portfolio Table 106. Sandoz Recent Development Table 107. Changchun High Tech Company Information Table 108. Changchun High Tech Business Overview Table 109. Changchun High Tech Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 110. Changchun High Tech Biosimilar Drug Product Portfolio Table 111. Changchun High Tech Recent Development Table 112. Innovent Company Information Table 113. Innovent Business Overview Table 114. Innovent Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 115. Innovent Biosimilar Drug Product Portfolio Table 116. Innovent Recent Development Table 117. North America Biosimilar Drug Market Size Growth Rate (CAGR) by Country (K Dose): 2021 VS 2025 VS 2032 Table 118. North America Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 119. North America Biosimilar Drug Sales Market Share by Country (2021-2026) Table 120. North America Biosimilar Drug Sales Forecast by Country (2027-2032) & (K Dose) Table 121. North America Biosimilar Drug Sales Market Share Forecast by Country (2027-2032) Table 122. North America Biosimilar Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. North America Biosimilar Drug Market Size by Country (2021-2026) & (US$ Million) Table 124. North America Biosimilar Drug Market Share by Country (2021-2026) Table 125. North America Biosimilar Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. North America Biosimilar Drug Market Share Forecast by Country (2027-2032) Table 127. Europe Biosimilar Drug Market Size Growth Rate (CAGR) by Country (K Dose): 2021 VS 2025 VS 2032 Table 128. Europe Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 129. Europe Biosimilar Drug Sales Market Share by Country (2021-2026) Table 130. Europe Biosimilar Drug Sales Forecast by Country (2027-2032) & (K Dose) Table 131. Europe Biosimilar Drug Sales Market Share Forecast by Country (2027-2032) Table 132. Europe Biosimilar Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Europe Biosimilar Drug Market Size by Country (2021-2026) & (US$ Million) Table 134. Europe Biosimilar Drug Market Share by Country (2021-2026) Table 135. Europe Biosimilar Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Europe Biosimilar Drug Market Share Forecast by Country (2027-2032) Table 137. Asia-Pacific Biosimilar Drug Market Size Growth Rate (CAGR) by Country (K Dose): 2021 VS 2025 VS 2032 Table 138. Asia-Pacific Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 139. Asia-Pacific Biosimilar Drug Sales Market Share by Country (2021-2026) Table 140. Asia-Pacific Biosimilar Drug Sales Forecast by Country (2027-2032) & (K Dose) Table 141. Asia-Pacific Biosimilar Drug Sales Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific Biosimilar Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific Biosimilar Drug Market Size by Country (2021-2026) & (US$ Million) Table 144. Asia-Pacific Biosimilar Drug Market Share by Country (2021-2026) Table 145. Asia-Pacific Biosimilar Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Asia-Pacific Biosimilar Drug Market Share Forecast by Country (2027-2032) Table 147. Latin America Biosimilar Drug Market Size Growth Rate (CAGR) by Country (K Dose): 2021 VS 2025 VS 2032 Table 148. Latin America Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 149. Latin America Biosimilar Drug Sales Market Share by Country (2021-2026) Table 150. Latin America Biosimilar Drug Sales Forecast by Country (2027-2032) & (K Dose) Table 151. Latin America Biosimilar Drug Sales Market Share Forecast by Country (2027-2032) Table 152. Latin America Biosimilar Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Latin America Biosimilar Drug Market Size by Country (2021-2026) & (US$ Million) Table 154. Latin America Biosimilar Drug Market Share by Country (2021-2026) Table 155. Latin America Biosimilar Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Latin America Biosimilar Drug Market Share Forecast by Country (2027-2032) Table 157. Middle East and Africa Biosimilar Drug Market Size Growth Rate (CAGR) by Country (K Dose): 2021 VS 2025 VS 2032 Table 158. Middle East and Africa Biosimilar Drug Sales by Country (2021-2026) & (K Dose) Table 159. Middle East and Africa Biosimilar Drug Sales Market Share by Country (2021-2026) Table 160. Middle East and Africa Biosimilar Drug Sales Forecast by Country (2027-2032) & (K Dose) Table 161. Middle East and Africa Biosimilar Drug Sales Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa Biosimilar Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa Biosimilar Drug Market Size by Country (2021-2026) & (US$ Million) Table 164. Middle East and Africa Biosimilar Drug Market Share by Country (2021-2026) Table 165. Middle East and Africa Biosimilar Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Middle East and Africa Biosimilar Drug Market Share Forecast by Country (2027-2032) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Biosimilar Drug Distributors List Table 170. Biosimilar Drug Customers List Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. Biosimilar Drug Image Figure 2. Global Biosimilar Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Drug Sales (2021-2032) & (K Dose) Figure 5. Injection Image Figure 6. Global Injection Sales YoY Growth (2021-2032) & (K Dose) Figure 7. Tablets Image Figure 8. Global Tablets Sales YoY Growth (2021-2032) & (K Dose) Figure 9. Other Types Image Figure 10. Global Other Types Sales YoY Growth (2021-2032) & (K Dose) Figure 11. Global Biosimilar Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Biosimilar Drug Market Share by Type 2025 VS 2032 Figure 13. North America Biosimilar Drug Sales Market Share in Volume by Type in 2025 Figure 14. North America Biosimilar Drug Sales Market Share in Value by Type in 2025 Figure 15. Europe Biosimilar Drug Sales Market Share in Volume by Type in 2025 Figure 16. Europe Biosimilar Drug Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Biosimilar Drug Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Biosimilar Drug Sales Market Share in Value by Type in 2025 Figure 19. Latin America Biosimilar Drug Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Biosimilar Drug Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Biosimilar Drug Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Biosimilar Drug Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Biosimilar Drug Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Ankylosing Spondylitis Image Figure 26. Global Ankylosing Spondylitis Sales YoY Growth (2021-2032) & (K Dose) Figure 27. Tumor Image Figure 28. Global Tumor Sales YoY Growth (2021-2032) & (K Dose) Figure 29. Rheumatoid Arthrtis Image Figure 30. Global Rheumatoid Arthrtis Sales YoY Growth (2021-2032) & (K Dose) Figure 31. Cardiovascular Image Figure 32. Global Cardiovascular Sales YoY Growth (2021-2032) & (K Dose) Figure 33. Other Application Image Figure 34. Global Other Application Sales YoY Growth (2021-2032) & (K Dose) Figure 35. Global Biosimilar Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Biosimilar Drug Market Share by Application 2025 VS 2032 Figure 37. North America Biosimilar Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Biosimilar Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Biosimilar Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Biosimilar Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Biosimilar Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Biosimilar Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Biosimilar Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Biosimilar Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Biosimilar Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Biosimilar Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Biosimilar Drug Sales by Country: 2021 VS 2025 VS 2032 (K Dose) Figure 48. North America Biosimilar Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Biosimilar Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Biosimilar Drug Sales by Country: 2021 VS 2025 VS 2032 (K Dose) Figure 52. Europe Biosimilar Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Biosimilar Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Biosimilar Drug Sales by Country: 2021 VS 2025 VS 2032 (K Dose) Figure 56. Asia-Pacific Biosimilar Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Biosimilar Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Biosimilar Drug Sales by Country: 2021 VS 2025 VS 2032 (K Dose) Figure 60. Latin America Biosimilar Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Biosimilar Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Biosimilar Drug Sales by Country: 2021 VS 2025 VS 2032 (K Dose) Figure 64. Middle East and Africa Biosimilar Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Biosimilar Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Biosimilar Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Biosimilar Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Tablets
  • Other Types
Applications
  • Ankylosing Spondylitis
  • Tumor
  • Rheumatoid Arthrtis
  • Cardiovascular
  • Other Application
Companies covered
  • CP Guojian Pharma
  • Biotech Pharma
  • Celgen Pharma
  • Henlius
  • Amgen
  • Eli Lilly
  • Sandoz
  • Changchun High Tech
  • Innovent

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biosimilar Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Biosimilar Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Biosimilar Drug Market by Type
  6. 1.3.1 Injection
  7. 1.3.2 Tablets
  8. 1.3.3 Other Types
  9. 1.4 Global Biosimilar Drug Market Size by Type
  10. 1.4.1 Global Biosimilar Drug Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Biosimilar Drug Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Biosimilar Drug Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Biosimilar Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Biosimilar Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Biosimilar Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Biosimilar Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Biosimilar Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Biosimilar Drug Industry Trends
  2. 2.2 Biosimilar Drug Industry Drivers
  3. 2.3 Biosimilar Drug Industry Opportunities and Challenges
  4. 2.4 Biosimilar Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Biosimilar Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Biosimilar Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Biosimilar Drug Price (2021-2026)
  4. 3.4 Global Biosimilar Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilar Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Biosimilar Drug Company, Product Type & Application
  7. 3.7 Global Biosimilar Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilar Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilar Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilar Drug Tier 1, Tier 2, and Tier 3
4 Biosimilar Drug Regional Status and Outlook
  1. 4.1 Global Biosimilar Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Biosimilar Drug Historic Market Size by Region
  3. 4.2.1 Global Biosimilar Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Biosimilar Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Biosimilar Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Biosimilar Drug Forecasted Market Size by Region
  7. 4.3.1 Global Biosimilar Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Biosimilar Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Biosimilar Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Biosimilar Drug by Application
  1. 5.1 Biosimilar Drug Market by Application
  2. 5.1.1 Ankylosing Spondylitis
  3. 5.1.2 Tumor
  4. 5.1.3 Rheumatoid Arthrtis
  5. 5.1.4 Cardiovascular
  6. 5.1.5 Other Application
  7. 5.2 Global Biosimilar Drug Market Size by Application
  8. 5.2.1 Global Biosimilar Drug Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Biosimilar Drug Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Biosimilar Drug Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Biosimilar Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Biosimilar Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Biosimilar Drug Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Biosimilar Drug Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Biosimilar Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 CP Guojian Pharma
  2. 6.1.1 CP Guojian Pharma Company Information
  3. 6.1.2 CP Guojian Pharma Business Overview
  4. 6.1.3 CP Guojian Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 CP Guojian Pharma Biosimilar Drug Product Portfolio
  6. 6.1.5 CP Guojian Pharma Recent Developments
  7. 6.2 Biotech Pharma
  8. 6.2.1 Biotech Pharma Company Information
  9. 6.2.2 Biotech Pharma Business Overview
  10. 6.2.3 Biotech Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Biotech Pharma Biosimilar Drug Product Portfolio
  12. 6.2.5 Biotech Pharma Recent Developments
  13. 6.3 Celgen Pharma
  14. 6.3.1 Celgen Pharma Company Information
  15. 6.3.2 Celgen Pharma Business Overview
  16. 6.3.3 Celgen Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Celgen Pharma Biosimilar Drug Product Portfolio
  18. 6.3.5 Celgen Pharma Recent Developments
  19. 6.4 Henlius
  20. 6.4.1 Henlius Company Information
  21. 6.4.2 Henlius Business Overview
  22. 6.4.3 Henlius Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Henlius Biosimilar Drug Product Portfolio
  24. 6.4.5 Henlius Recent Developments
  25. 6.5 Amgen
  26. 6.5.1 Amgen Company Information
  27. 6.5.2 Amgen Business Overview
  28. 6.5.3 Amgen Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Amgen Biosimilar Drug Product Portfolio
  30. 6.5.5 Amgen Recent Developments
  31. 6.6 Eli Lilly
  32. 6.6.1 Eli Lilly Company Information
  33. 6.6.2 Eli Lilly Business Overview
  34. 6.6.3 Eli Lilly Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Eli Lilly Biosimilar Drug Product Portfolio
  36. 6.6.5 Eli Lilly Recent Developments
  37. 6.7 Sandoz
  38. 6.7.1 Sandoz Company Information
  39. 6.7.2 Sandoz Business Overview
  40. 6.7.3 Sandoz Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sandoz Biosimilar Drug Product Portfolio
  42. 6.7.5 Sandoz Recent Developments
  43. 6.8 Changchun High Tech
  44. 6.8.1 Changchun High Tech Company Information
  45. 6.8.2 Changchun High Tech Business Overview
  46. 6.8.3 Changchun High Tech Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Changchun High Tech Biosimilar Drug Product Portfolio
  48. 6.8.5 Changchun High Tech Recent Developments
  49. 6.9 Innovent
  50. 6.9.1 Innovent Company Information
  51. 6.9.2 Innovent Business Overview
  52. 6.9.3 Innovent Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Innovent Biosimilar Drug Product Portfolio
  54. 6.9.5 Innovent Recent Developments
7 North America by Country
  1. 7.1 North America Biosimilar Drug Sales by Country
  2. 7.1.1 North America Biosimilar Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Biosimilar Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Biosimilar Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Biosimilar Drug Market Size by Country
  6. 7.2.1 North America Biosimilar Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Biosimilar Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Biosimilar Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Biosimilar Drug Sales by Country
  2. 8.1.1 Europe Biosimilar Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Biosimilar Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Biosimilar Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Biosimilar Drug Market Size by Country
  6. 8.2.1 Europe Biosimilar Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Biosimilar Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Biosimilar Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Biosimilar Drug Sales by Country
  2. 9.1.1 Asia-Pacific Biosimilar Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Biosimilar Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Biosimilar Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Biosimilar Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Biosimilar Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Biosimilar Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Biosimilar Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Biosimilar Drug Sales by Country
  2. 10.1.1 South America Biosimilar Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Biosimilar Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Biosimilar Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Biosimilar Drug Market Size by Country
  6. 10.2.1 South America Biosimilar Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Biosimilar Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Biosimilar Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Biosimilar Drug Sales by Country
  2. 11.1.1 Middle East and Africa Biosimilar Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Biosimilar Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Biosimilar Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Biosimilar Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Biosimilar Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Biosimilar Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Biosimilar Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Biosimilar Drug Value Chain Analysis
  2. 12.1.1 Biosimilar Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Biosimilar Drug Production Mode & Process
  7. 12.2 Biosimilar Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Biosimilar Drug Distributors
  10. 12.2.3 Biosimilar Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst